comparemela.com

Page 3 - Nasdaq Mdna News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Medicenna Presents Phase 1/2 ABILITY Study Data

New data show that MDNA11 boosted the lymphocyte population by 2-fold without inducing significant increases in eosinophils (associated with toxicity) .

United statesSuperkine immunotherapiesGeok chooMedicenna therapeutics corpYork academy of sciencesAnnual frontiersNew york academyFahar merchantExhibiting potent tumor growth controlPreclinical modelsPreferential expansionAdvanced solid tumorsEngland journalOrphan drugNasdaq mdnaMedicenna therapeutics corp

Medicenna Presents Preclinical Data Demonstrating

Fc-MDNA413 suppresses pro-tumor immune pathways by simultaneously inhibiting IL-4 / IL-13 mediated signaling and proliferation via the Type II IL-4.

United statesMedicenna superkineSuperkine immunotherapiesMedicenna therapeutics corpAmerican association for cancer researchAmerican associationCancer researchFahar merchantAntagonist engineeredTarget tumor associated macrophagesMyeloid cellsOrphan drugNasdaq mdnaMedicenna therapeutics corp

Medicenna Announces Management Change and Appoints

Phase 1/2 ABILITY study of MDNA11 remains on track for an update on additional safety pharmacokinetic (PK), and pharmacodynamic (PD) data in low-dose.

United statesPaul smithMann muhsinPeter lloydElizabeth williamsMartin bexonSuperkine immunotherapiesBruce pearceL bruce pearceUniversity of new york at buffaloAlfredp sloan foundationRegulatory affairsUniversity of newcastle upon tyneDevelopment advisory committeeHarvard medical schoolExchange commission

vimarsana © 2020. All Rights Reserved.